Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 126 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: arginine vasopressin Clear all
Completed Phase 2Phase 3 Interventional Results available

Early Use of Vasopressin in Post-Fontan Management

NCT03088345
View directory record Official record
Conditions
Circulatory Perfusion Disorder, Congenital Heart Disease, Single-ventricle
Interventions
Vasopressin, Arginine, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Weeks to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regulation of Arginine-vasopressin (AVP)

NCT02626832
View directory record Official record
Conditions
Schizophrenia, Depression
Interventions
Procedural
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 6, 2026, 4:33 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

NCT04064346
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Hoover, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 6, 2026, 4:33 PM EDT
Completed No phase listed Observational

Atrial and Brain Natriuretic Peptides in Bronchiolitis

NCT00347880
View directory record Official record
Conditions
Bronchiolitis
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
37 Weeks to 2 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2012 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT03487913
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Lixivaptan
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 6, 2026, 4:33 PM EDT
Not yet recruiting Phase 4 Interventional

Phenotype Guided Vasoactive Medication During Kidney Transplantation

NCT07633600
View directory record Official record
Conditions
Kidney Transplant, Fluid Management
Interventions
Phenotype-Guided Vasoactive Management
Drug
Lead sponsor
Jennifer Cutler
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Not applicable Interventional

Post-Operative Water Load Following Transsphenoidal Pituitary Surgery

NCT02727686
View directory record Official record
Conditions
Hyponatremia, Pituitary Adenoma
Interventions
Water Load (WL) Post-Operative Day 1
Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Not applicable Interventional Results available

Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants

NCT01318278
View directory record Official record
Conditions
Hypotension
Interventions
Dopamine, Arginine Vasopressin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 24 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure

NCT02606253
View directory record Official record
Conditions
Heart Failure
Interventions
tolvaptan, Chlorothiazide, Metolazone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome

NCT06635629
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Desmopressin, Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

NCT02507284
View directory record Official record
Conditions
Irritable Mood, Huntington's Disease
Interventions
SRX246, Placebo
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vasopressin in Intraabdominal Pressure Elevation

NCT03707054
View directory record Official record
Conditions
Intracranial Pressure Increase, Abdominal Compartment Syndrome
Interventions
Study Arm
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 72 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Withdrawn Phase 2 Interventional

Intranasal Oxytocin and Learning in Autism

NCT02090829
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Syntocinon (synthetic oxytocin), Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identifying Oxytocin Deficiency in Adults With Pituitary Disease

NCT06460948
View directory record Official record
Conditions
Arginine Vasopressin Deficiency, Oxytocin Deficiency
Interventions
Norethindrone Acetate-Ethinyl Estradiol
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Terminated No phase listed Observational

Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator

NCT06426407
View directory record Official record
Conditions
Shock, Septic
Interventions
Vasopressin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors

NCT03676361
View directory record Official record
Conditions
Kidney Damage
Interventions
Desmopressin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Oxytocin and Arginine Vasopressin in Pain Relief

NCT01328561
View directory record Official record
Conditions
Placebo Analgesia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

The Role of Vasopressin in the Social Deficits of Autism

NCT01962870
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Vasopressin, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 12 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Withdrawn Phase 4 Interventional

NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock

NCT02454348
View directory record Official record
Conditions
Shock, Septic
Interventions
Vasopressin, Norepinephrine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 6, 2026, 4:33 PM EDT
Recruiting Not applicable Interventional

DDAVP for Pituitary Adenoma

NCT04569591
View directory record Official record
Conditions
Cushing's Disease, Pituitary Adenoma
Interventions
Desmopressin acetate
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 4 Interventional

Vasopressin for Septic Shock Pragmatic Trial

NCT06217562
View directory record Official record
Conditions
Septic Shock
Interventions
Vasopressin, Recommendation to use a lower initiation threshold for vasopressin, Recommendation to use a higher initiation threshold for vasopressin
Drug · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
3,959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Burley, Idaho • American Fork, Utah • Cedar City, Utah + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Influence of Osmotic Stimulation of Vasopressin on Autonomic Function

NCT04233606
View directory record Official record
Conditions
Water Stress, Body Water Dehydration
Interventions
Hypertonic Saline, Normal Saline
Other
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Early Phase 1 Interventional

The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology

NCT04463394
View directory record Official record
Conditions
Hypotension, Fontan Physiology
Interventions
Vasopressin
Drug
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 6, 2026, 4:33 PM EDT